Intralesional radioimmunotherapy in the treatment of malignant glioma: clinical and experimental findings
- 1 January 2003
- book chapter
- Published by Springer Nature
- Vol. 88, 69-75
- https://doi.org/10.1007/978-3-7091-6090-9_12
Abstract
In the last two decades radioimmunotherapy has been used as an additional treatment option for malignant glioma in several centers. More than 400 patients have been reported, who were treated in the framework of different studies. Most of them received labelled antibodies to tenascin, an extracellular matrix-glycoprotein, which is expressed in high amounts in malignant gliomas. We report side effects and survival time of 46 patients, treated after surgical resection and conventional radiotherapy with intralesionally injected labelled (131-Iodine) antibodies to tenascin.Keywords
This publication has 31 references indexed in Scilit:
- Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant GliomasJournal of Clinical Oncology, 2002
- Pre-Targeted Locoregional Radioimmunotherapy with 90Y-biotin in Glioma Patients: Phase I Study and Preliminary Therapeutic ResultsCancer Biotherapy & Radiopharmaceuticals, 2001
- Disruption of intracerebral progression of rat C6 glioblastoma by in vivo treatment with anti-CD44 monoclonal antibodyJournal of Neurosurgery, 2000
- 131I Radioconjugated Antibodies for the Locoregional Radioimmunotherapy of High-grade Malignant Glioma: Phase I and II StudyActa Oncologica, 1999
- Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991Journal of Neurosurgery, 1998
- Biodistribution of 125I-MAb 425 in a Human Glioma Xenograft Model: Effect of ChloroquineHybridoma, 1997
- Multivariate analysis of prognostic factors in 106 patients with malignant gliomaEuropean Journal Of Cancer, 1996
- Phase I studies of treatment of malignant gliomas and neoplastic meningitis with131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab?)2-a preliminary reportJournal of Neuro-Oncology, 1995
- Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trialInternational Journal of Radiation Oncology*Biology*Physics, 1992
- The Localisation of Radiolabeled Murine Monoclonal Antibody 81C6 and its Fab Fragment in Human Glioma Xenografts in Athymic MiceBritish Journal Of Neurosurgery, 1988